Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

inova logo

Falls Church, VA – Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National…

Read More

Diversity and Inclusion in Clinical Trials

holding hands

Stephanie Van Bebber is Senior Director, Inova Schar Cancer Institute Clinical Trials Office at Inova. As we celebrate Clinical Trials Day this year, we recognize the extraordinary work that is done by research teams every day to ensure that future healthcare treatments and interventions are safe and effective. The date of May 20th honors James…

Read More

Review of Inova COVID-19 Cases Lends Insight into Ventilator Mortality Risks

Falls Church, VA – An Inova study of COVID-19 patients sheds light on how patients have responded to advanced ICU interventions. Researchers sought to paint a realistic picture of survival expectations within a single, well-resourced healthcare system, over the patient’s entire length of stay. Christopher King, MD, transplant pulmonologist and critical care physician at Inova Fairfax…

Read More

Inova’s Dr. Aragon-Ching Part of International Team Showing Benefit of Immunotherapy in Bladder Cancer Treatment

image of a hand outstretched towards a sunny lake

Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine. The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given…

Read More

Inova Joins Virginia Department of Health and George Mason University in Pediatric COVID-19 Serology Study

abstract COVID image

Inova Health System is partnering with George Mason University (GMU) and the Virginia Department of Health (VDH) to conduct a COVID-19 serology (antibody) study to analyze the incidence of COVID-19 in children in Northern Virginia.  Inova is recruiting approximately 1,000 children, ages 0 to 19 for the study. Child participants will be asked to provide…

Read More

FDA Approves Cutting-Edge Cancer Drug from Inova Schar Cancer Institute Clinical Trial

dart board with a red dart in the center bulls eye

Inova’s Dr. John Deeken served as the site principal investigator for this prestigious study In groundbreaking news for the medical and cancer research community, the Food and Drug Administration (FDA) approved a new, breakthrough cancer drug, larotrectinib, or Vitrakvi®, that targets specific genetic mutations in adult and pediatric patients. This is only the second tissue-agnostic…

Read More

NPR Visits Inova to Document Infant-Health Research Study

nurse swabbing a newborn baby

Inova’s vaginal seeding study featured on NPR’s Morning Edition NPR’s Morning Edition has profiled the groundbreaking vaginal seeding study at Inova Women’s Hospital that aims to discover if babies born by C-section will benefit from a swab of their mother’s microbes. The article explains how vaginal seeding “was developed in response to the sharp rise…

Read More